Advertise With Us
Subscribe to Newsletter
IB-Logo

[email protected]

  • Markets
  • Business & Finance
    • Forex
    • Stocks
  • Finance
  • Economy
  • Politics
  • Real Estate
  • Crypto
  • AI
  • Health
  • Research
  • Sports
  • More
    • Tech
    • Science
    • Weather
  • Markets
  • Business & Finance
    • Forex
    • Stocks
  • Finance
  • Economy
  • Politics
  • Real Estate
  • Crypto
  • AI
  • Health
  • Research
  • Sports
  • More
    • Tech
    • Science
    • Weather
IB-Logo
Advertise With Us
Subscribe to Newsletter
  • Markets
  • Business & Finance
    • Forex
    • Stocks
  • Finance
  • Economy
  • Politics
  • Real Estate
  • Crypto
  • AI
  • Health
  • Research
  • Sports
  • More
    • Tech
    • Science
    • Weather
  • Markets
  • Business & Finance
    • Forex
    • Stocks
  • Finance
  • Economy
  • Politics
  • Real Estate
  • Crypto
  • AI
  • Health
  • Research
  • Sports
  • More
    • Tech
    • Science
    • Weather

Future Pak and Cycle Pharma’s buyout proposals are rejected by Vanda

Adopted to prohibit any entity from obtaining a shareholding of more than ten percent without board permission.

admin by admin
June 20, 2024
in Business & Finance
0
Future Pak and Cycle Pharma’s buyout proposals are rejected by Vanda
  • (Reuters) – Vanda (NASDAQ: VNDA) Pharmaceuticals said on Wednesday that it had turned down buyout proposals from contract manufacturer Future Pak and UK-based Cycle Pharmaceutical, stating that both bids undervalued the American pharmaceutical company.
  • Vanda has turned down Future Pak’s takeover offer three times already. Vanda implemented a “poison pill” shareholder rights plan after its first bid from Future Pak in April to lessen the likelihood of a hostile acquisition.
  • As part of a last-ditch effort to acquire Vanda, Future Pak increased the monetary element of its takeover bid last week. Along with previously suggested contingent value rights of around $4.27 per share, it increased the percentage to $8.50–$9.00 per share.
  • Vanda would be valued at $466 million based on Cycle Pharma’s earlier this month takeover bid, which called for $8 in cash per share.
  • The proposals were turned down by the Vanda board on Wednesday, with the reason given that “both significantly undervalue Vanda and are not in the best interests of the Company and its shareholders.”
Source: investing

RelatedPosts

BTS PRO X
Markets

BTS PRO X: 5 Powerful Reasons This New Financial Giant Stands Out

November 17, 2026
Gulf Stock Markets
Politics

Gulf Stock Markets Gain as Trump Signals Pause on Iran Strikes

November 9, 2026
Houthi Strikes
Politics

Houthi Strikes on Saudi Arabia Hit Riyadh Aramco Tower (2026)

November 9, 2026
Financial Services
Business & Finance

Financial Services Career Opportunities: High Schoolers Dive In

November 9, 2026
WLFI Token Buyback Program
Business & Finance

WLFI Token Buyback Program Launched by World Liberty Financial

November 9, 2026
Global Economic Risks
Economy

Global Economic Risks Shift: AI Debt and Sovereign Deficits

November 4, 2026

Facebook

IB-Logo

Latest News & Updates
Premier source for business,
financial news, analysis and insights.

  • Fact Checking Policy
  • Editorial Policy
  • Financial Disclaimer
  • Advertising & Sponsored Content Policy
Advertise With Us
  • About Us
  • Contact Us
  • Privacy Policy

© All Rights Reserved 2026 InvestorBytes.

No Result
View All Result
  • About Us
  • Advertising & Sponsored Content Policy
  • Contact Us
  • Editorial Policy
  • Fact-Checking Policy
  • Financial Disclaimer
  • Main Page
  • Markets
  • Privacy Policy

© 2026 InvestorBytes. All rights reserved.

Advertise With Us

No thanks.

Catch up with InvestorBytes

Your weekly dose of market insights and business news, delivered right to your inbox.

No thanks.